Core Insights - Turn Therapeutics has appointed Arthur Golden to its Board of Directors to enhance governance, oversight, and strategic execution as the company advances its late-stage programs [1][3] - Mr. Golden brings over 40 years of experience in corporate law, governance, and strategic advisory, particularly in M&A transactions and regulatory affairs [2][4] - The appointment is expected to strengthen Turn's position for long-term growth and value creation, especially as it navigates critical phases in its development [3] Company Overview - Turn Therapeutics is a clinical-stage biotechnology company focused on developing next-generation therapies for dermatology, wound care, and infectious diseases [1][6] - The company has received three FDA clearances for its proprietary formulations and is advancing late-stage clinical programs in eczema and onychomycosis [6] - Turn is also engaged in global health initiatives, including thermostable vaccine delivery aimed at underserved areas [6] Leadership Experience - Arthur Golden has extensive experience advising multinational organizations on regulatory, operational, and corporate development functions [2][4] - He has served as a Director for several NYSE companies for over 30 years and has been recognized for excellence in corporate and governance advisory [5] - His role as Senior Counsel at Davis Polk & Wardwell LLP has equipped him with insights into guiding Fortune 500 companies through transformative transactions [2][4]
Turn Therapeutics Appoints Arthur Golden to Board of Directors